Abstracts tagged "outcome measures and pulmonary complications"

Abstract Number: 1713 • 2012 ACR/ARHP Annual Meeting
Developing an Index for Disease Activity and Therapeutic Response in Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Delivering A Consensus On Domains
Lesley Ann Saketkoo¹, Dörte Huscher², Dinesh Khanna³, Paul F. Dellaripa⁴, Kevin Flaherty⁵, Chester V. Oddis⁶, Kristine Phillips⁷, Athol U. Wells⁸, Christopher P. Denton⁹, Oliver Distler¹⁰, Otylia M. Kowal-Bielecka¹¹, Romy Christmann¹², Nora Sandorfi¹³, David Pittrow¹⁴, Vibeke Strand¹⁵, James R. Seibold¹⁶, Kevin K. Brown¹⁷ and Eric L. Matteson¹⁸, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Department of Critical Care and Pulmonary Medicine, University of Michigan, Ann Arbor, MI, ⁶Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheumatology, University of Michigan, Ann Arbor, MI, ⁸Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ¹⁰Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹¹Department of Rheumatology and Internal Medicine, Medical University in Bialystok, Bialystok, Poland, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Rheumatology, Thomas Jefferson Univ Med Coll, Philadelphia, PA, ¹⁴Institute of Clinical Pharmacology - University of Dresden, Dresden, Germany, ¹⁵Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ¹⁶Scleroderma Research Consultants LLC, Avon, CT, ¹⁷Autoimmune Lung Center, National Jewish Hospital, Denver, CO, ¹⁸Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Lack of reliable and valid measures of disease activity and clinical response in patients with connective tissue disease (CTD)-related interstitial lung disease (ILD) makes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].